



Published in final edited form as:

Science. 2008 August 15; 321(5891): 960–964. doi:10.1126/science.1159689.

## Small CRISPR RNAs Guide Antiviral Defense in Prokaryotes

Stan J. J. Brouns<sup>1,\*</sup>, Matthijs M. Jore<sup>1,\*</sup>, Magnus Lundgren<sup>1</sup>, Edze R. Westra<sup>1</sup>, Rik J. H. Slijkhuis<sup>1</sup>, Ambrosius P. L. Snijders<sup>2</sup>, Mark J. Dickman<sup>2</sup>, Kira S. Makarova<sup>3</sup>, Eugene V. Koonin<sup>3</sup>, and John van der Oost<sup>1,†</sup>

<sup>1</sup>Laboratory of Microbiology, Department of Agrotechnology and Food Sciences, Wageningen University, Dreijenplein 10, 6703 HB Wageningen, Netherlands <sup>2</sup>Biological and Environmental Systems, Department of Chemical and Process Engineering, University of Sheffield, Mappin Street, Sheffield S1 3JD, UK <sup>3</sup>National Center for Biotechnology Information, National Library of Medicine, NIH, Bethesda, MD 20894, USA

### Abstract

Prokaryotes acquire virus resistance by integrating short fragments of viral nucleic acid into clusters of regularly interspaced short palindromic repeats (CRISPRs). Here we show how virus-derived sequences contained in CRISPRs are used by CRISPR-associated (Cas) proteins from the host to mediate an antiviral response that counteracts infection. After transcription of the CRISPR, a complex of Cas proteins termed Cascade cleaves a CRISPR RNA precursor in each repeat and retains the cleavage products containing the virus-derived sequence. Assisted by the helicase Cas3, these mature CRISPR RNAs then serve as small guide RNAs that enable Cascade to interfere with virus proliferation. Our results demonstrate that the formation of mature guide RNAs by the CRISPR RNA endonuclease subunit of Cascade is a mechanistic requirement for antiviral defense.

The clusters of regularly interspaced short palindromic repeat (CRISPR)-based defense system protects many bacteria and archaea against invading conjugative plasmids, transposable elements, and viruses (1–8). Resistance is acquired by incorporating short stretches of invading DNA sequences in genomic CRISPR loci (1, 9, 10). These integrated sequences are thought to function as a genetic memory that prevents the host from being infected by viruses containing this recognition sequence. A number of CRISPR-associated (*cas*) genes (11–13) has been reported to be essential for the phage-resistant phenotype (1). However, the molecular mechanism of this adaptive and inheritable defense system in prokaryotes has remained unknown.

The *Escherichia coli* K12 CRISPR/*cas* system comprises eight *cas* genes: *cas3* (predicted HD-nuclease fused to a DEAD-box helicase), five genes designated *casABCDE*, *cas1* (predicted integrase) (13), and the endoribonuclease gene *cas2* (14) (Fig. 1A and table S1). In separate experiments, each Cas protein was tagged at both the N and C terminus and

<sup>†</sup>To whom correspondence should be addressed. john.vanderoost@wur.nl.

\*These authors contributed equally to this work.

Supporting Online Material: [www.sciencemag.org/cgi/content/full/321/5891/960/DC1](http://www.sciencemag.org/cgi/content/full/321/5891/960/DC1) Materials and Methods

produced along with the complete set of untagged Cas proteins (15). Affinity purification of the tagged component enabled the identification of a protein complex composed of five Cas proteins: CasA, CasB, CasC, CasD, and CasE (Fig. 1B). The complex, denoted Cascade (CRISPR-associated complex for antiviral defense), could be isolated from *E. coli* lysates using any of the tagged subunits of the complex as bait, except for CasA.

The function of Cascade was studied by analyzing the effect of in-frame *cas* gene knockouts (16) on the formation of transcripts of the CRISPR region in *E. coli* K12 (Fig. 1A). Northern analysis of total RNA with single-stranded spacer sequences as a probe showed transcription of the CRISPR region in the direction downstream of the *cas2* gene (Figs. 1A and 2A) and no transcription in the opposite direction. Analysis of control strains (wild type and a non-*cas* gene knockout) revealed a small CRISPR-RNA (crRNA) product of ~57 nucleotides (Fig. 2A). The same product was present in much higher amounts in the *casA*, *casB*, and *casC* knockout strains but absent from strains lacking the overlapping genes *casD* and *casE* (Fig. 2A). The small crRNAs seem to be cleaved from a multi-unit crRNA precursor (pre-crRNA) (7, 17, 18), as is evident from the presence of two and three repeat-spacer units (~120 and ~180 nucleotides) that show up in the *casA*, *casB*, and *casC* strains (Fig. 2A). The *casE* strain contained a large pre-crRNA, suggesting that the disruption of this gene prevents pre-crRNA cleavage.

To study the accumulation and cleavage patterns of crRNAs in the *E. coli* K12 knockout strains in more detail and to rule out any effects of the gene disruptions on the expression of downstream or upstream *cas* genes, the five subunits of Cascade and the K12-type pre-crRNA were expressed in *E. coli* BL21(DE3), which lacks endogenous *cas* genes (19). Northern analysis showed that crRNAs of ~57 nucleotides were only produced in strains containing the Cascade complex (Fig. 2B). By omitting the individual subunits one by one, it became apparent that the small crRNA was absent only in the strain that lacked *casE* (Fig. 2B), indicating that this is the only Cascade subunit essential for pre-crRNA cleavage.

Activity assays with purified Cascade showed that the complex is capable of cleaving the *E. coli* K12 pre-crRNA into fragments of ~57 nucleotides in vitro (Fig. 2C). However, no cleavage was observed with either pre-crRNA from *E. coli* UTI89, which contains repeats with a different sequence (20), or a non-crRNA template (Fig. 2C). The RNA cleavage reaction proceeded in the absence of divalent metal ions and adenosine triphosphate and reached saturation level within 5 min. To investigate whether the CasE subunit is sufficient for pre-crRNA cleavage activity, it was overproduced as a fusion with the *E. coli* maltose binding protein (MalE). Like the complete Cascade, the CasE fusion protein cleaved only the K12-type pre-crRNA (Fig. 2D), showing that CasE is an unusual endoribonuclease that does not require the other Cascade subunits. We cannot rule out the possibility that pre-crRNA cleavage is an auto-catalytic, ribozyme-like reaction, in which CasE is an essential RNA chaperone.

CasE belongs to one of the numerous families of repeat-associated mysterious proteins, the largest and most diverse class of Cas proteins (12, 13). The crystal structure of a CasE homolog from *Thermus thermophilus* HB8 shows that the protein contains two domains with a ferredoxin-like fold, and displays overall structural similarity to a variety of RNA-

binding proteins (13, 21). On the basis of structure and amino acid conservation analysis of this protein family (fig. S1), the invariant residue His<sup>20</sup> was mutated to Ala to analyze the effect on pre-crRNA cleavage. Northern blots indicated that crRNAs of ~57 nucleotides were no longer formed in the strain containing Cascade-CasE<sup>H20A</sup> (Fig. 2E). Moreover, although the mutated CasE was still incorporated into Cascade, the pre-crRNA cleaving ability of purified Cascade was abolished (Fig. 2F), providing further support for the essential role of CasE in pre-crRNA cleavage and suggesting that the conserved His residue is involved in catalysis.

The crRNA cleavage sites were examined by simultaneous expression of K12-type pre-crRNA and Cascade. Under these conditions, the purification of Cascade yielded substantial amounts of copurified RNAs of ~57 nucleotides (Fig. 3A). Cloning and sequencing of this Cascade-bound RNA revealed that 85% of the clones [67 out of 79 clones (67/79)] were derived from crRNAs, of which 78% (52/67) started with the last eight bases of the repeat sequence (AUAAACCG) (Fig. 3B and fig. S2). This well-defined 5' end was followed by a complete spacer sequence and a less well-defined 3' sequence ending in the next repeat region. A transcript of a single palindromic repeat can fold as a stable stem-loop of seven base pairs, which may facilitate recognition by RNA-binding Cas proteins (8, 20), such as CasE. The pre-crRNA cleavage site (PCS) appeared to be located immediately upstream of the 3' terminal base of the stem-loop formed by the repeat (Fig. 3B). The clone library did not contain crRNAs of 61 nucleotides, which would be the result of a single endonuclease cleavage event in each repeat, given the size of a repeat (29 nucleotides) and most spacers (32 nucleotides). Instead, in agreement with experimental observations (Figs. 2 and 3A), the crRNAs were truncated at the 3' end by at least two guanosine bases from the endonuclease cleavage site, removing several stem-forming bases.

To test whether crRNA-loaded Cascade gives rise to phage resistance, two artificial CRISPRs were designed against phage Lambda ( $\lambda$ ). Each of these CRISPRs targeted four essential  $\lambda$  genes (fig. S3). The coding CRISPR (C<sub>1-4</sub>) produced crRNAs complementary to both the mRNA and the coding strand of these four genes, whereas the template CRISPR (T<sub>1-4</sub>) targeted only the template strand of the same proto-spacer regions (fig. S3). A nontargeting CRISPR containing wild-type (WT) spacers with no similarity to the phage genome served as a control. Plaque assays with *E. coli* showed that the introduction of either one of these anti- $\lambda$  phage CRISPRs in a strain expressing only Cascade did not result in reduced sensitivity of the host to a virulent Lambda phage ( $\lambda_{\text{vir}}$ ) (Fig. 4A). However, strains that expressed Cascade and Cas3 were much less sensitive to phage infection. The template CRISPR rendered the strain insensitive to the phage at the highest phage titer tested (>10<sup>7</sup>-fold less sensitive than the control strain), whereas the coding CRISPR reduced the sensitivity 10<sup>2</sup>-fold (Fig. 4A) and produced plaques with a diameter  $\sim \frac{1}{10}$  of the standard  $\lambda$  plaque. The phage resistance phenotype was lost when Cascade was omitted (Fig. 4A), proving that both Cascade and Cas3 are required in this process. Moreover, strains containing Cas3 and Cascade-CasE<sup>H20A</sup> displayed a sensitive phenotype, which shows that pre-crRNA cleavage is mechanistically required for phage resistance. The co-expression of Cas1 and Cas2 had no effect on the sensitivity profile of the strain (Fig. 4A), suggesting that these proteins are involved in other stages of the CRISPR/*cas* mechanism. Plaque assays

with single anti- $\lambda$  spacers (fig. S3) showed that the total reduction of sensitivity observed with the four anti- $\lambda$  spacers ( $C_{1-4}$  and  $T_{1-4}$ ) (Fig. 4A) results from a synergistic effect of the individual spacers ( $C_1$  to  $T_4$ ) (Fig. 4B).

Our results demonstrate that a complex of five Cas proteins is responsible for the maturation of pre-crRNA to small crRNAs that are critical for mediating an antiviral response. These mature crRNAs contain the antiviral spacer unit flanked by short RNA sequences derived from the repeat on either side termed the 5' and 3' handle, which may serve as conserved binding sites for Cascade subunits, as has been suggested previously (20). The Cascade-bound crRNA serves as a guide to direct the complex to viral nucleic acids to mediate an antiviral response. We hypothesize that crRNAs target virus DNA, because anti- $\lambda$  CRISPRs of both polarities lead to a reduction of sensitivity to the phage. The model is supported by previous observations that virus-derived sequences are integrated into CRISPR loci, irrespective of their orientation in the virus genome (1–4, 7, 9,10,13). We conclude that the transcription of CRISPR regions—and the cleavage of pre-crRNA to mature crRNAs by Cas proteins—is the molecular basis of the antiviral defense stage of the CRISPR/*cas* system, which enables prokaryotes to effectively prevent phage predation.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.


## Acknowledgments

We thank T. Verweij, C. G. J. van Houte, and M. R. Beijer for experimental contributions and T. Goosen (Hogeschool van Arnhem en Nijmegen BioCentre), M. J. Young (Montana State University), T. Bisseling, and W. M. de Vos (Wageningen University) for helpful discussions. We are grateful for receiving strains from the KEIO collection distributed by National BioResource Project (National Institute of Genetics, Japan). We thank U. Dobrindt (University of Würzburg) for sending genomic material of *E. coli* UTI89. This work was financially supported by a Vici grant from the Dutch Organization for Scientific Research (Nederlandse Organisatie voor Wetenschappelijk Onderzoek) and a Marie Curie grant from the European Union. M.L. was supported by the Wenner-Gren Foundations.


## References and Notes

1. Barrangou R, et al. *Science*. 2007; 315:1709. [PubMed: 17379808]
2. Mojica FJ, Diez-Villasenor C, Garcia-Martinez J, Soria E. *J Mol Evol*. 2005; 60:174. [PubMed: 15791728]
3. Pourcel C, Salvignol G, Vergnaud G. *Microbiology*. 2005; 151:653. [PubMed: 15758212]
4. Bolotin A, Quinquis B, Sorokin A, Ehrlich SD. *Microbiology*. 2005; 151:2551. [PubMed: 16079334]
5. Godde JS, Bickerton A. *J Mol Evol*. 2006; 62:718. [PubMed: 16612537]
6. Tyson GW, Banfield JF. *Environ Microbiol*. 2008; 10:200. [PubMed: 17894817]
7. Lillestøl RK, Redder P, Garrett RA, Brügger K. *Archaea*. 2006; 2:59. [PubMed: 16877322]
8. Sorek R, Kunin V, Hugenholtz P. *Nat Rev Microbiol*. 2008; 6:181. [PubMed: 18157154]
9. Horvath P, et al. *J Bacteriol*. 2008; 190:1401. [PubMed: 18065539]
10. Deveau H, et al. *J Bacteriol*. 2008; 190:1390. [PubMed: 18065545]
11. Jansen R, Embden JD, Gaastra W, Schouls LM. *Mol Microbiol*. 2002; 43:1565. [PubMed: 11952905]
12. Haft DH, Selengut J, Mongodin EF, Nelson KE. *PLoS Comput Biol*. 2005; 1:e60. [PubMed: 16292354]

13. Makarova KS, Grishin NV, Shabalina SA, Wolf YI, Koonin EV. Biol Direct. 2006; 1:7. [PubMed: 16545108]
14. Beloglazova N, et al. J Biol Chem. 2008; 283:20361. [PubMed: 18482976]
15. Materials and methods are available as supporting material on *Science* Online.
16. Baba T, Mori H. Methods Mol Biol. 2008; 416:171. [PubMed: 18392967]
17. Tang TH, et al. Proc Natl Acad Sci USA. 2002; 99:7536. [PubMed: 12032318]
18. Tang TH, et al. Mol Microbiol. 2005; 55:469. [PubMed: 15659164]
19. Kim JF, Jeong H, Lenski RE. personal communication.
20. Kunin V, Sorek R, Hugenholtz P. Genome Biol. 2007; 8:R61. [PubMed: 17442114]
21. Ebihara A, et al. Protein Sci. 2006; 15:1494. [PubMed: 16672237]


**Fig. 1.**

The composition of the Cascade complex. **(A)** Schematic diagram of the CRISPR/*cas* gene cluster of *E. coli* K12 W3110. Repeats and spacers are indicated by diamonds and rectangles, respectively. A palindrome in the repeat is marked by convergently pointing arrows. Protein family nomenclature is as described in (11, 12). **(B)** Coomassie blue—stained SDS-polyacrylamide gel of the affinity purified protein complex using either the N-terminal StrepII-tag (S) or C-terminal His-tag (H) of each of the subunits CasB, CasC, CasD, or CasE as bait. Asterisks indicate the 5.5 kD larger double-tagged subunits. Marker sizes in kilodaltons on the left; location of untagged subunits on the right.

**Fig. 2.**


Cascade cleaves CRISPR RNA precursors into small RNAs of ~57 nucleotides (marked by arrows). **(A)** Northern analysis of total RNA of WT *E. coli* K12 (WT), a non-*cas* gene knockout (*u*, *uidA*,  $\beta$ -glucuronidase), and Cascade gene knockouts using the single-stranded spacer sequence BG2349 (table S2) as a probe. **(B)** Northern blot as in (A) of total RNA from *E. coli* BL21 (DE3) expressing the *E. coli* K12 pre-crRNA and either the complete or incomplete Cascade complex. **(C)** Activity assays with purified Cascade using in vitro transcribed  $\alpha$ -<sup>32</sup>P-uridine triphosphate-labeled pre-crRNA from *E. coli* K12 (repeat sequence: GAGUCCCCGCCAGCGGGGAUAAACCG), *E. coli* UTI89 (repeat sequence: GUUCACUGCCGUACAGGCAGCUUAGAAA), and non-crRNA as substrates. **(D)** Activity assays as shown in (C) for 15 min with purified MalE-LacZ $\alpha$  and MalE-CasE fusion proteins. **(E)** Northern blot as shown in (B) with Cascade or Cascade-CasE<sup>H20A</sup>. **(F)** Activity assays as shown in (C) for 30 min with purified Cascade or Cascade-CasE<sup>H20A</sup>.





**Fig. 3.** Cleaved crRNAs remain bound by Cascade. **(A)** Denaturing polyacryl-amide gel showing the crRNA (marked by the arrow) isolated from purified Cascade in the absence and presence of co-expressed pre-crRNA. **(B)** Secondary structure of pre-crRNA repeats and example sequences of cloned crRNAs indicating the PCS and crRNA handles.



**Fig. 4.**

Engineered CRISPRs confer resistance to  $\lambda$  in the presence of Cascade and Cas3. **(A)** Effect of the presence of different sets of *cas* genes on the sensitivity of *E. coli* to phage  $\lambda_{vir}$ . Cells were equipped with one of two engineered CRISPRs containing four anti- $\lambda$  spacers each (fig. S3). The C<sub>1-4</sub> CRISPR produces crRNA complementary to the coding strand and mRNA of  $\lambda_{vir}$ , and the T<sub>1-4</sub> CRISPR targets only the template strand. The sensitivity of each strain to phage  $\lambda_{vir}$  is represented as a histogram of the efficiency of plaquing, which is the plaque count ratio of the anti- $\lambda$  CRISPR to that of the nontargeting control CRISPR. **(B)** Effect of single anti- $\lambda$  spacers (fig. S3) on the sensitivity of *E. coli* to  $\lambda_{vir}$ . Error bars indicate 1 SD.